Standard

18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review). / Petriev, V.M.; Tishchenko, V.K.; Krasikova, R. N.

In: Pharmaceutical Chemistry Journal, Vol. 50, No. 4, 08.2016, p. 209-220.

Research output: Contribution to journal › Review article › peer-review

Harvard

Petriev, VM, Tishchenko, VK & Krasikova, RN 2016, '18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review)', Pharmaceutical Chemistry Journal, vol. 50, no. 4, pp. 209-220. https://doi.org/10.1007/s11094-016-1425-y

APA

Petriev, V. M., Tishchenko, V. K., & Krasikova, R. N. (2016). 18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review). Pharmaceutical Chemistry Journal, 50(4), 209-220. https://doi.org/10.1007/s11094-016-1425-y

Vancouver

Petriev VM, Tishchenko VK, Krasikova RN. 18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review). Pharmaceutical Chemistry Journal. 2016 Aug;50(4):209-220. https://doi.org/10.1007/s11094-016-1425-y

Author

Petriev, V.M. ; Tishchenko, V.K. ; Krasikova, R. N. / 18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review). In: Pharmaceutical Chemistry Journal. 2016 ; Vol. 50, No. 4. pp. 209-220.

BibTeX

@article{15e7687a21f14b248ac10d047c34f58c,
title = "18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review)",
abstract = "This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations (RPP) based on labeled glucose derivatives. Most attention is paid to 2-[F-18]fluoro-2-deoxy-D-glucose (F-18-FDG), a glucose analog labeled with fluorine-18 (T (1/2) = 110 min) and the only radiotracer for glycolysis, which is used in 90% of clinical studies using positron emission tomography (PET). We describe approaches to the synthesis of F-18-FDG and state-of-the-art automated technologies allowing tens of clinical doses of RPP for PET investigations of patients to be prepared. The main areas of use of PET with F-18-FDG in the diagnosis of various tumors are discussed, as is the potential for using glucose derivatives with other radionuclides (Ga-68, I-123, Tc-99m, Re-188) as tracers for use in PET and SPECT diagnosis.",
keywords = "2-[F-18]Fluoro-2-deoxy-D-glucose, F-18-FDG, radiopharmaceutical preparations, radiotracers, oncological diagnosis, positron emission tomography, PET, single-photon emission computed tomography, SPECT, planar scintigraphy, PS, labeled glucose derivatives, POSITRON-EMISSION-TOMOGRAPHY, STANDARDIZED UPTAKE VALUE, DIFFERENTIATED THYROID-CARCINOMA, RECURRENT COLORECTAL-CANCER, GERM-CELL TUMORS, FDG-PET, BIOLOGICAL EVALUATION, DEOXYGLUCOSE DERIVATIVES, FLUORODEOXYGLUCOSE PET, BREAST-CANCER",
author = "V.M. Petriev and V.K. Tishchenko and Krasikova, {R. N.}",
year = "2016",
month = aug,
doi = "10.1007/s11094-016-1425-y",
language = "Английский",
volume = "50",
pages = "209--220",
journal = "Pharmaceutical Chemistry Journal",
issn = "0091-150X",
publisher = "Springer Nature",
number = "4",

}

RIS

TY - JOUR

T1 - 18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review)

AU - Petriev, V.M.

AU - Tishchenko, V.K.

AU - Krasikova, R. N.

PY - 2016/8

Y1 - 2016/8

N2 - This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations (RPP) based on labeled glucose derivatives. Most attention is paid to 2-[F-18]fluoro-2-deoxy-D-glucose (F-18-FDG), a glucose analog labeled with fluorine-18 (T (1/2) = 110 min) and the only radiotracer for glycolysis, which is used in 90% of clinical studies using positron emission tomography (PET). We describe approaches to the synthesis of F-18-FDG and state-of-the-art automated technologies allowing tens of clinical doses of RPP for PET investigations of patients to be prepared. The main areas of use of PET with F-18-FDG in the diagnosis of various tumors are discussed, as is the potential for using glucose derivatives with other radionuclides (Ga-68, I-123, Tc-99m, Re-188) as tracers for use in PET and SPECT diagnosis.

AB - This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations (RPP) based on labeled glucose derivatives. Most attention is paid to 2-[F-18]fluoro-2-deoxy-D-glucose (F-18-FDG), a glucose analog labeled with fluorine-18 (T (1/2) = 110 min) and the only radiotracer for glycolysis, which is used in 90% of clinical studies using positron emission tomography (PET). We describe approaches to the synthesis of F-18-FDG and state-of-the-art automated technologies allowing tens of clinical doses of RPP for PET investigations of patients to be prepared. The main areas of use of PET with F-18-FDG in the diagnosis of various tumors are discussed, as is the potential for using glucose derivatives with other radionuclides (Ga-68, I-123, Tc-99m, Re-188) as tracers for use in PET and SPECT diagnosis.

KW - 2-[F-18]Fluoro-2-deoxy-D-glucose

KW - F-18-FDG

KW - radiopharmaceutical preparations

KW - radiotracers

KW - oncological diagnosis

KW - positron emission tomography

KW - PET

KW - single-photon emission computed tomography

KW - SPECT

KW - planar scintigraphy

KW - PS

KW - labeled glucose derivatives

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - STANDARDIZED UPTAKE VALUE

KW - DIFFERENTIATED THYROID-CARCINOMA

KW - RECURRENT COLORECTAL-CANCER

KW - GERM-CELL TUMORS

KW - FDG-PET

KW - BIOLOGICAL EVALUATION

KW - DEOXYGLUCOSE DERIVATIVES

KW - FLUORODEOXYGLUCOSE PET

KW - BREAST-CANCER

U2 - 10.1007/s11094-016-1425-y

DO - 10.1007/s11094-016-1425-y

M3 - Обзорная статья

VL - 50

SP - 209

EP - 220

JO - Pharmaceutical Chemistry Journal

JF - Pharmaceutical Chemistry Journal

SN - 0091-150X

IS - 4

ER -

ID: 9431353